Nektar Therapeutics Stock Price, News & Analysis (NASDAQ:NKTR)

$44.99 0.06 (0.13 %)
(As of 11/17/2017 10:59 AM ET)
Previous Close$44.99
Today's Range$46.98 - $44.20
52-Week Range$11.41 - $46.98
Volume3.67 million shs
Average Volume1.64 million shs
Market Capitalization$7.08 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.37

About Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics logoNektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its programs include Immuno-oncology (I-O), Immunology, Pain-NKTR-181 and Oncology-ONZEALD. It is developing medicines designed to directly or indirectly modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Pharmaceuticals
  • Sector: Biotechnology & Medical Research - NEC
  • Symbol: NASDAQ:NKTR
  • CUSIP: 64026810
  • Web: www.nektar.com
Debt:
  • Debt-to-Equity Ratio: 2.91%
  • Current Ratio: 4.14%
  • Quick Ratio: 3.99%
Sales & Book Value:
  • Annual Sales: $165.44 million
  • Price / Sales: 42.82
  • Book Value: $0.53 per share
  • Price / Book: 84.89
Profitability:
  • Trailing EPS: ($0.71)
  • Net Income: ($153,520,000.00)
  • Net Margins: -42.08%
  • Return on Equity: -190.68%
  • Return on Assets: -19.50%
Misc:
  • Employees: 468
  • Outstanding Shares: 157,470,000
 

Frequently Asked Questions for Nektar Therapeutics (NASDAQ:NKTR)

What is Nektar Therapeutics' stock symbol?

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) released its quarterly earnings results on Tuesday, November, 7th. The biopharmaceutical company reported $0.37 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.21 by $0.16. The biopharmaceutical company earned $152.90 million during the quarter, compared to analysts' expectations of $126.50 million. Nektar Therapeutics had a negative return on equity of 190.68% and a negative net margin of 42.08%. The company's revenue for the quarter was up 321.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.32) earnings per share. View Nektar Therapeutics' Earnings History.

When will Nektar Therapeutics make its next earnings announcement?

Nektar Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 7th 2018. View Earnings Estimates for Nektar Therapeutics.

Where is Nektar Therapeutics' stock going? Where will Nektar Therapeutics' stock price be in 2017?

13 analysts have issued 12-month price objectives for Nektar Therapeutics' stock. Their predictions range from $20.00 to $50.00. On average, they expect Nektar Therapeutics' share price to reach $36.64 in the next year. View Analyst Ratings for Nektar Therapeutics.

What are Wall Street analysts saying about Nektar Therapeutics stock?

Here are some recent quotes from research analysts about Nektar Therapeutics stock:

  • 1. Mizuho analysts commented, "We believe raising our PT from $30 to $45 more accurately reflects conservative assumptions surrounding the value add of NKTR-214 within US- based NSCLC patients. Going forward, we believe NKTR-214 will remain a major value driver for the company." (11/8/2017)
  • 2. According to Zacks Investment Research, "Nektar reported wider-than-expected loss in the second quarter of 2017 with revenue missing estimates. The launch of its drugs, Movantik and Adynovate, has been on track with both the products performing impressively. Additionally, regular partnerships have enhanced the company’s financial position. Nektar stands to receive significant sales milestone plus royalties for Movantik under the license agreement with AstraZeneca, which might substantially boost its financial position. Also, its recent co-development deal with Lilly for NKTR-358 is also encouraging. However, Nektar relies heavily on partners for revenues. Partnership-related setbacks may weigh heavily on the company, while disappointing products sales could leave an adverse impact on its financial results. Nektar also has a promising pipeline, with several updates lined up for the next several quarters. The company’s shares have outperformed the industry in the year so far." (8/11/2017)
  • 3. BTIG Research analysts commented, "Nektar announced positive results from the Phase 3 SUMMIT-07 study of NKTR-181, its novel, proprietary, abuse-resistant opioid for pain. NKTR- 181 met all important primary and secondary efficacy endpoints in the 610- patient study, and the molecule appeared well tolerated, materially derisking the program. At its primary endpoint at week 12 postrandomization, average pain scores increased 1.46 points on the Numeric Rating Scale with placebo, vs. 0.92 points for NKTR-181 (p=0.0019); other secondary endpoints were also as positive. NKTR-181 has been FastTracked, a rarity for an opioid, and with this highly positive study in hand, there is a possibility for rapid progression of NKTR-181, and a material partnership. With 181's success, and with the potential for additional meaningful catalysts near-term, we raise our NKTR price target to $27." (3/21/2017)
  • 4. Jefferies Group LLC analysts commented, "The unexpected Ph 3 success for '181 brings this once very promising mu-opioid analgesic asset back to life. In our view, it could become NKTR's largest and most profitable product as it squarely addresses the 'opioid epidemic'. Mgt hopes to partner the drug by YE. We believe '181 could bring significant value (modeling 30% royalties and $250M+ in milestones) to the company as early as 2020. With this asset now unencumbered, NKTR now fits our M&A thesis." (3/21/2017)
  • 5. Aegis analysts commented, "NKTR-181 met its primary endpoint in the phase III Summit-07 trial - increase Price Target to $25. Yesterday morning, Netkar Therapeutics announced that NKTR-181 met its primary endpoint of mean change in weekly average numeric rating scale (NRS) pain score for the randomized, double-blind treatment period from the end of the open-label titration period (baseline) to week 12. Average pain scores measured at week 12 from baseline increased 1.46 for placebo vs. 0.92 for NKTR-181 (p=0.0019). We had not previously factored in revenue from NKTR-181 into our price target. As a result of the positive phase III results, we now include such revenue under partnering assumptions in the US and raise our price target from $21 to $24." (3/20/2017)

Who are some of Nektar Therapeutics' key competitors?

Who are Nektar Therapeutics' key executives?

Nektar Therapeutics' management team includes the folowing people:

  • Robert B. Chess, Independent Chairman of the Board (Age 60)
  • Howard W. Robin, President, Chief Executive Officer, Director (Age 64)
  • Gilbert M. Labrucherie J.D., Chief Financial Officer, Senior Vice President (Age 45)
  • John L. Nicholson, Chief Operating Officer, Senior Vice President (Age 65)
  • Jillian B. Thomsen, Senior Vice President - Finance, Chief Accounting Officer (Age 51)
  • Stephen K. Doberstein Ph.D., Senior Vice President, Chief Scientific Officer (Age 58)
  • Ivan Philip Gergel M.D., Senior Vice President - Drug Development & Chief Medical Officer (Age 56)
  • Maninder Hora Ph.D., Senior Vice President - Pharmaceutical Development and Manufacturing Operations (Age 63)
  • Jeff Robert Ajer, Independent Director (Age 55)
  • R. Scott Greer, Independent Director (Age 58)

Who owns Nektar Therapeutics stock?

Nektar Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Westfield Capital Management Co. LP (2.31%), Janus Henderson Group PLC (2.11%), JPMorgan Chase & Co. (1.49%), Bank of New York Mellon Corp (1.32%), First Trust Advisors LP (1.06%) and Principal Financial Group Inc. (0.93%). Company insiders that own Nektar Therapeutics stock include Christopher A Kuebler, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, R Scott Greer, Robert Chess, Roy A Whitfield, Stephen K Doberstein and Susan Wang. View Institutional Ownership Trends for Nektar Therapeutics.

Who sold Nektar Therapeutics stock? Who is selling Nektar Therapeutics stock?

Nektar Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP, Sei Investments Co., First Trust Advisors LP, Bank of New York Mellon Corp, Principal Financial Group Inc., New York State Common Retirement Fund, Rice Hall James & Associates LLC and Stoneridge Investment Partners LLC. Company insiders that have sold Nektar Therapeutics company stock in the last year include Christopher A Kuebler, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, Robert Chess and Stephen K Doberstein. View Insider Buying and Selling for Nektar Therapeutics.

Who bought Nektar Therapeutics stock? Who is buying Nektar Therapeutics stock?

Nektar Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Neuberger Berman Group LLC, Nationwide Fund Advisors, Artisan Partners Limited Partnership, Rothschild Asset Management Inc., Schwab Charles Investment Management Inc., BNP Paribas Arbitrage SA and Crossmark Global Holdings Inc.. Company insiders that have bought Nektar Therapeutics stock in the last two years include R Scott Greer and Roy A Whitfield. View Insider Buying and Selling for Nektar Therapeutics.

How do I buy Nektar Therapeutics stock?

Shares of Nektar Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nektar Therapeutics' stock price today?

One share of Nektar Therapeutics stock can currently be purchased for approximately $44.99.

How big of a company is Nektar Therapeutics?

Nektar Therapeutics has a market capitalization of $7.08 billion and generates $165.44 million in revenue each year. The biopharmaceutical company earns ($153,520,000.00) in net income (profit) each year or ($0.71) on an earnings per share basis. Nektar Therapeutics employs 468 workers across the globe.

How can I contact Nektar Therapeutics?

Nektar Therapeutics' mailing address is 455 Mission Bay Blvd S, SAN FRANCISCO, CA 94158-2158, United States. The biopharmaceutical company can be reached via phone at +1-415-4825300 or via email at [email protected]


MarketBeat Community Rating for Nektar Therapeutics (NASDAQ NKTR)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  351 (Vote Outperform)
Underperform Votes:  146 (Vote Underperform)
Total Votes:  497
MarketBeat's community ratings are surveys of what our community members think about Nektar Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Nektar Therapeutics (NASDAQ:NKTR)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 12 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.92)
Consensus Price Target: $36.64 (18.57% downside)

Consensus Price Target History for Nektar Therapeutics (NASDAQ:NKTR)

Price Target History for Nektar Therapeutics (NASDAQ:NKTR)

Analysts' Ratings History for Nektar Therapeutics (NASDAQ:NKTR)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/13/2017Canaccord GenuityBoost Price TargetBuy$35.00 -> $50.00N/AView Rating Details
11/15/2017Canaccord Genuity Group Inc.Boost Price TargetBuy$35.00 -> $50.00N/AView Rating Details
11/13/2017Roth CapitalSet Price TargetBuy$45.00N/AView Rating Details
11/14/2017MizuhoBoost Price TargetBuy$30.00 -> $45.00N/AView Rating Details
11/13/2017J P Morgan Chase & CoReiterated RatingPositive -> Buy$44.00N/AView Rating Details
11/8/2017Jefferies Group LLCReiterated RatingBuy$35.00N/AView Rating Details
11/7/2017Cowen and CompanyInitiated CoverageOutperformN/AView Rating Details
8/17/2017Evercore ISIInitiated CoverageIn -> In-Line$20.00HighView Rating Details
8/7/2017HC WainwrightInitiated CoverageBuy -> Buy$31.00LowView Rating Details
7/18/2017William BlairReiterated RatingOutperformLowView Rating Details
5/10/2017AegisReiterated RatingBuy$27.00HighView Rating Details
4/11/2017Piper Jaffray CompaniesReiterated RatingOverweight$29.00LowView Rating Details
3/21/2017BTIG ResearchBoost Price TargetPositive$22.00 -> $27.00MediumView Rating Details
9/30/2016Brean CapitalReiterated RatingBuy$23.00N/AView Rating Details
1/27/2016Janney Montgomery ScottInitiated CoverageBuy$21.00N/AView Rating Details
(Data available from 11/18/2015 forward)

Earnings

Earnings History and Estimates Chart for Nektar Therapeutics (NASDAQ:NKTR)

Earnings by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Earnings History by Quarter for Nektar Therapeutics (NASDAQ NKTR)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2018        
11/7/2017Q3 2017$0.21$0.37$126.50 million$152.90 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.35)($0.39)$33.64 million$34.60 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.40)($0.42)$29.43 million$24.73 millionViewListenView Earnings Details
3/1/2017Q416($0.26)($0.28)$40.83 million$37.45 millionViewListenView Earnings Details
11/3/2016Q316($0.36)($0.32)$32.42 million$36.30 millionViewN/AView Earnings Details
8/3/2016Q216($0.33)($0.36)$34.17 million$32.77 millionViewListenView Earnings Details
5/3/2016Q1($0.23)($0.14)$43.78 million$58.88 millionViewN/AView Earnings Details
3/1/2016Q4($0.42)($0.40)$28.82 million$39.40 millionViewListenView Earnings Details
11/5/2015Q315($0.30)($0.06)$44.30 million$60.00 millionViewN/AView Earnings Details
8/5/2015Q215($0.40)($0.40)$21.49 million$22.66 millionViewN/AView Earnings Details
4/30/2015Q115($0.40)$0.25$20.20 million$108.80 millionViewN/AView Earnings Details
2/24/2015Q414($0.36)($0.35)$12.30 million$19.55 millionViewN/AView Earnings Details
11/6/2014Q314$0.39$0.53$123.20 million$132.90 millionViewN/AView Earnings Details
7/31/2014Q214($0.38)($0.26)$19.76 million$28.50 millionViewListenView Earnings Details
5/7/2014Q114($0.35)($0.37)$38.68 million$19.80 millionViewListenView Earnings Details
2/26/2014Q413($0.17)($0.41)$49.26 million$31.15 millionViewN/AView Earnings Details
11/7/2013Q313($0.22)($0.14)$54.34 million$60.91 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.44)($0.37)$26.22 million$33.86 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.42)($0.48)$26.30 million$23.00 millionViewN/AView Earnings Details
11/9/2012Q312($0.39)($0.38)$21.02 million$18.41 millionViewN/AView Earnings Details
8/9/2012($0.33)($0.30)ViewN/AView Earnings Details
5/2/2012($0.33)($0.36)ViewN/AView Earnings Details
2/29/2012($0.47)($0.33)ViewN/AView Earnings Details
11/2/2011($0.37)($0.21)ViewN/AView Earnings Details
8/4/2011($0.31)($0.32)ViewN/AView Earnings Details
4/27/2011($0.27)($0.33)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Nektar Therapeutics (NASDAQ:NKTR)
2017 EPS Consensus Estimate: ($0.83)
2018 EPS Consensus Estimate: ($1.01)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.49)($0.31)($0.40)
Q2 20172($0.37)($0.29)($0.33)
Q3 20172$0.15$0.27$0.21
Q4 20173($0.40)($0.18)($0.31)
Q1 20182($0.32)($0.12)($0.22)
Q2 20182($0.32)($0.13)($0.23)
Q3 20182($0.33)($0.13)($0.23)
Q4 20181($0.33)($0.33)($0.33)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Nektar Therapeutics (NASDAQ:NKTR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Nektar Therapeutics (NASDAQ NKTR)

Insider Ownership Percentage: 6.10%
Institutional Ownership Percentage: 94.97%
Insider Trades by Quarter for Nektar Therapeutics (NASDAQ:NKTR)
Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Insider Trades by Quarter for Nektar Therapeutics (NASDAQ NKTR)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/13/2017John NicholsonCOOSell15,910$37.78$601,079.80View SEC Filing  
11/8/2017Stephen K DobersteinSVPSell396,323$29.00$11,493,367.00View SEC Filing  
11/6/2017Maninder HoraSVPSell5,117$25.07$128,283.19View SEC Filing  
11/1/2017Howard W RobinCEOSell83,334$23.57$1,964,182.38View SEC Filing  
10/9/2017Howard W RobinCEOSell83,333$24.20$2,016,658.60View SEC Filing  
10/5/2017Stephen K DobersteinSVPSell43,677$24.97$1,090,614.69View SEC Filing  
10/2/2017Gil M. LabrucherieCFOSell120,000$24.45$2,934,000.00View SEC Filing  
10/2/2017Ivan P GergelSVPSell100,000$24.14$2,414,000.00View SEC Filing  
9/22/2017Christopher A KueblerDirectorSell4,000$21.86$87,440.00View SEC Filing  
9/21/2017Robert ChessDirectorSell6,400$21.72$139,008.00View SEC Filing  
9/6/2017Howard W RobinCEOSell83,333$21.54$1,794,992.82View SEC Filing  
8/16/2017Howard W RobinCEOSell91,714$19.26$1,766,411.64View SEC Filing  
8/16/2017Jillian B. ThomsenCAOSell2,648$19.32$51,159.36View SEC Filing  
8/16/2017John NicholsonCOOSell3,177$19.32$61,379.64View SEC Filing  
8/16/2017Stephen K DobersteinSVPSell1,701$19.32$32,863.32View SEC Filing  
8/10/2017Roy A WhitfieldDirectorBuy35,000$17.95$628,250.00View SEC Filing  
7/18/2017Ivan P GergelSVPSell54,920$21.10$1,158,812.00View SEC Filing  
7/14/2017Lutz LingnauDirectorSell30,000$20.76$622,800.00View SEC Filing  
7/12/2017Ivan P GergelSVPSell45,080$21.08$950,286.40View SEC Filing  
7/11/2017Ivan P GergelSVPSell8,389$21.04$176,504.56View SEC Filing  
5/16/2017Gil M. LabrucherieCFOSell3,179$19.55$62,149.45View SEC Filing  
5/16/2017Howard W RobinCEOSell8,388$19.55$163,985.40View SEC Filing  
5/16/2017John NicholsonCOOSell3,146$19.55$61,504.30View SEC Filing  
5/16/2017Stephen K DobersteinSVPSell1,701$19.55$33,254.55View SEC Filing  
5/15/2017Robert ChessDirectorSell5,000$19.79$98,950.00View SEC Filing  
4/17/2017Robert ChessDirectorSell5,000$18.72$93,600.00View SEC Filing  
4/7/2017Lutz LingnauDirectorSell7,000$20.05$140,350.00View SEC Filing  
4/5/2017Christopher A KueblerDirectorSell15,000$21.88$328,200.00View SEC Filing  
4/5/2017Maninder HoraSVPSell180,000$21.70$3,906,000.00View SEC Filing  
3/20/2017Jillian B. ThomsenSVPSell112,500$19.69$2,215,125.00View SEC Filing  
3/3/2017Gil M. LabrucherieCFOSell200,000$15.16$3,032,000.00View SEC Filing  
2/16/2017Gil M. LabrucherieCFOSell2,359$13.14$30,997.26View SEC Filing  
2/16/2017Howard W RobinCEOSell8,636$13.14$113,477.04View SEC Filing  
2/16/2017Ivan P GergelSVPSell1,457$13.14$19,144.98View SEC Filing  
2/16/2017John NicholsonCOOSell3,237$13.14$42,534.18View SEC Filing  
2/8/2017Howard W RobinCEOSell87,500$13.04$1,141,000.00View SEC Filing  
2/3/2017John NicholsonCOOSell75,000$12.39$929,250.00View SEC Filing  
1/17/2017Howard W RobinCEOSell87,500$12.35$1,080,625.00View SEC Filing  
11/17/2016Howard W RobinCEOSell93,458$13.88$1,297,197.04View SEC Filing  
10/24/2016R Scott GreerDirectorBuy15,000$13.50$202,500.00View SEC Filing  
10/4/2016Howard W. RobinCEOSell87,500$17.06$1,492,750.00View SEC Filing  
9/16/2016Christopher A. KueblerDirectorSell7,500$19.13$143,475.00View SEC Filing  
9/15/2016Robert ChessDirectorSell12,000$19.21$230,520.00View SEC Filing  
9/1/2016Howard W. RobinCEOSell87,500$17.83$1,560,125.00View SEC Filing  
8/16/2016Gil M. LabrucherieCFOSell3,305$17.56$58,035.80View SEC Filing  
8/16/2016Howard W. RobinCEOSell11,817$17.56$207,506.52View SEC Filing  
8/16/2016John NicholsonCOOSell3,317$17.56$58,246.52View SEC Filing  
8/16/2016Stephen K. DobersteinSVPSell1,336$17.56$23,460.16View SEC Filing  
8/1/2016Robert ChessDirectorSell5,000$17.26$86,300.00View SEC Filing  
7/11/2016Jillian B ThomsenCAOSell100,000$15.09$1,509,000.00View SEC Filing  
7/1/2016Robert ChessDirectorSell5,000$14.10$70,500.00View SEC Filing  
5/17/2016Gil M LabrucherieSVPSell836$13.58$11,352.88View SEC Filing  
5/17/2016Howard W RobinCEOSell2,170$13.58$29,468.60View SEC Filing  
5/17/2016Jillian B ThomsenCAOSell724$13.58$9,831.92View SEC Filing  
5/17/2016John NicholsonCFOSell856$13.58$11,624.48View SEC Filing  
4/25/2016Lutz LingnauDirectorSell15,000$16.27$244,050.00View SEC Filing  
2/17/2016Howard W. RobinCEOSell2,147$11.92$25,592.24View SEC Filing  
2/17/2016Jillian B. ThomsenCAOSell716$11.92$8,534.72View SEC Filing  
2/17/2016Maninder HoraSVPSell963$11.92$11,478.96View SEC Filing  
2/10/2016Gil M. LabrucherieSVPSell11,666$11.49$134,042.34View SEC Filing  
2/10/2016Howard W. RobinCEOSell66,666$11.49$765,992.34View SEC Filing  
2/10/2016Jillian B. ThomsenCAOSell15,000$11.49$172,350.00View SEC Filing  
1/20/2016Lutz LingnauDirectorSell15,000$14.51$217,650.00View SEC Filing  
1/19/2016Gil M. LabrucherieSVPSell11,667$14.12$164,738.04View SEC Filing  
1/19/2016Howard W. RobinCEOSell66,667$14.12$941,338.04View SEC Filing  
1/19/2016Jillian B. ThomsenCAOSell15,000$14.12$211,800.00View SEC Filing  
12/4/2015Christopher A. KueblerDirectorSell15,000$15.82$237,300.00View SEC Filing  
12/3/2015Gil M. LabrucherieSVPSell45,001$15.87$714,165.87View SEC Filing  
12/3/2015Howard W. RobinCEOSell125,001$15.87$1,983,765.87View SEC Filing  
12/3/2015Jillian B. ThomsenCAOSell15,000$15.87$238,050.00View SEC Filing  
11/20/2015Susan WangDirectorSell85,000$15.02$1,276,700.00View SEC Filing  
11/11/2015Gil M. LabrucherieSVPSell45,000$13.52$608,400.00View SEC Filing  
11/11/2015Howard W. RobinCEOSell125,000$13.52$1,690,000.00View SEC Filing  
11/11/2015Jillian B. ThomsenCAOSell15,000$13.52$202,800.00View SEC Filing  
10/28/2015Lutz LingnauDirectorSell12,500$12.00$150,000.00View SEC Filing  
10/6/2015Gil M. LabrucherieSVPSell45,000$10.99$494,550.00View SEC Filing  
10/6/2015Howard W. RobinCEOSell125,000$10.99$1,373,750.00View SEC Filing  
10/6/2015Jillian B. ThomsenCAOSell15,000$10.99$164,850.00View SEC Filing  
9/23/2015Gil M. LabrucherieSVPSell44,999$13.04$586,786.96View SEC Filing  
9/23/2015Howard W. RobinCEOSell124,999$13.04$1,629,986.96View SEC Filing  
9/23/2015Jillian B. ThomsenCAOSell10,000$13.04$130,400.00View SEC Filing  
8/13/2015Gil M LabrucherieSVPSell33,333$10.89$362,996.37View SEC Filing  
8/13/2015Howard W RobinCEOSell58,333$10.89$635,246.37View SEC Filing  
7/14/2015Gil M LabrucherieSVPSell33,334$11.78$392,674.52View SEC Filing  
7/14/2015Howard W RobinCEOSell58,334$11.78$687,174.52View SEC Filing  
6/29/2015Susan WangDirectorSell30,000$12.70$381,000.00View SEC Filing  
6/19/2015Robert ChessDirectorSell15,000$11.81$177,150.00View SEC Filing  
6/15/2015Lutz LingnauDirectorSell25,000$11.15$278,750.00View SEC Filing  
12/29/2014Robert ChessDirectorSell29,500$15.34$452,530.00View SEC Filing  
12/22/2014Jillian B ThomsenCAOSell5,000$15.56$77,800.00View SEC Filing  
12/1/2014Gil M LabrucherieSVPSell120,000$17.02$2,042,400.00View SEC Filing  
12/1/2014Howard W RobinCEOSell350,000$17.01$5,953,500.00View SEC Filing  
11/25/2014Howard W RobinCEOSell600,000$15.25$9,150,000.00View SEC Filing  
11/24/2014Gil M LabrucherieSVPSell10,500$15.04$157,920.00View SEC Filing  
11/24/2014Howard W RobinCEOSell132,800$15.02$1,994,656.00View SEC Filing  
11/24/2014Lutz LingnauDirectorSell15,000$15.02$225,300.00View SEC Filing  
11/3/2014Gil M LabrucherieSVPSell9,900$13.78$136,422.00View SEC Filing  
8/5/2013Roy WhitfieldDirectorSell12,500$12.41$155,125.00View SEC Filing  
9/14/2012Dennis L WingerDirectorBuy5,000$9.18$45,900.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Nektar Therapeutics (NASDAQ:NKTR)

Latest Headlines for Nektar Therapeutics (NASDAQ NKTR)

Source:
DateHeadline
Bullish Options Positioning Continues in Nektar Therapeutics (NKTR) -Susquehanna - StreetInsider.comBullish Options Positioning Continues in Nektar Therapeutics (NKTR) -Susquehanna - StreetInsider.com
www.streetinsider.com - November 18 at 8:03 AM
 Brokerages Expect Nektar Therapeutics (NKTR) Will Announce Quarterly Sales of $39.54 Million Brokerages Expect Nektar Therapeutics (NKTR) Will Announce Quarterly Sales of $39.54 Million
www.americanbankingnews.com - November 17 at 9:14 AM
Nektar Therapeutics (NKTR) COO John Nicholson Sells 15,910 SharesNektar Therapeutics (NKTR) COO John Nicholson Sells 15,910 Shares
www.americanbankingnews.com - November 15 at 8:22 PM
Nektar Therapeutics stock rockets toward near 17-year high after upbeat trial data - MarketWatchNektar Therapeutics' stock rockets toward near 17-year high after upbeat trial data - MarketWatch
www.marketwatch.com - November 15 at 6:48 AM
New Research Collaboration Between BioXcel Therapeutics and Nektar to Evaluate BXCL701 in Combination with NKTR-214 in Multiple Oncology IndicationsNew Research Collaboration Between BioXcel Therapeutics and Nektar to Evaluate BXCL701 in Combination with NKTR-214 in Multiple Oncology Indications
globenewswire.com - November 13 at 9:55 PM
Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) Report First Data for NKTR-214 in Combination with OPDIVO (nivolumab)Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) Report First Data for NKTR-214 in Combination with OPDIVO (nivolumab)
www.streetinsider.com - November 13 at 9:55 PM
Nektar Therapeutics (NKTR) Has Jumped To A New High On Study ResultsNektar Therapeutics (NKTR) Has Jumped To A New High On Study Results
www.nasdaq.com - November 13 at 9:55 PM
Nektar Therapeutics (NKTR) Presents At Society For Immunotherapy Of Cancer - SlideshowNektar Therapeutics (NKTR) Presents At Society For Immunotherapy Of Cancer - Slideshow
seekingalpha.com - November 13 at 9:55 PM
Analyst: Nektar Has A Handful Of Milestones Ahead In 2018Analyst: Nektar Has A Handful Of Milestones Ahead In 2018
finance.yahoo.com - November 13 at 9:55 PM
Nektar/Bristol-Myers' Combo Trial Positive in Phase I/IINektar/Bristol-Myers' Combo Trial Positive in Phase I/II
finance.yahoo.com - November 13 at 9:55 PM
Why Nektar Therapeutics Shares Are Rallying 13.8% TodayWhy Nektar Therapeutics Shares Are Rallying 13.8% Today
finance.yahoo.com - November 13 at 9:55 PM
This Biotech Just Neared A 17-Year High On Strong Cancer RegimenThis Biotech Just Neared A 17-Year High On Strong Cancer Regimen
finance.yahoo.com - November 13 at 9:55 PM
Combination of Opdivo and Nektars NKTR-214 show positive effect in advanced lung cancer in Phase 1/2 study - Seeking AlphaCombination of Opdivo and Nektar's NKTR-214 show positive effect in advanced lung cancer in Phase 1/2 study - Seeking Alpha
seekingalpha.com - November 13 at 4:55 PM
Why Roku, GGP, and Nektar Therapeutics Jumped Today - Motley FoolWhy Roku, GGP, and Nektar Therapeutics Jumped Today - Motley Fool
www.fool.com - November 13 at 4:55 PM
Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) Report First Data for NKTR-214 in Combination with ... - StreetInsider.comNektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) Report First Data for NKTR-214 in Combination with ... - StreetInsider.com
www.streetinsider.com - November 13 at 4:55 PM
Why Roku, GGP, and Nektar Therapeutics Jumped TodayWhy Roku, GGP, and Nektar Therapeutics Jumped Today
finance.yahoo.com - November 13 at 4:55 PM
Nektar Therapeutics: Encouraging Data Revealed At SITC - Seeking AlphaNektar Therapeutics: Encouraging Data Revealed At SITC - Seeking Alpha
seekingalpha.com - November 13 at 9:00 AM
Nektar Therapeutics stock rockets toward near 17-year high after upbeat trial dataNektar Therapeutics' stock rockets toward near 17-year high after upbeat trial data
finance.yahoo.com - November 13 at 9:00 AM
Nektar Therapeutics up 25% premarket on encouraging preclinical data on immune system stimulator NKTR-214Nektar Therapeutics up 25% premarket on encouraging preclinical data on immune system stimulator NKTR-214
seekingalpha.com - November 13 at 8:37 AM
Nektar Therapeutics (NKTR) Given Average Rating of "Buy" by BrokeragesNektar Therapeutics (NKTR) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 13 at 5:38 AM
Nektar to Webcast Presentation at Jefferies 2017 London Healthcare ConferenceNektar to Webcast Presentation at Jefferies 2017 London Healthcare Conference
finance.yahoo.com - November 12 at 11:01 AM
Investors Purchase Large Volume of Nektar Therapeutics Put Options (NKTR)Investors Purchase Large Volume of Nektar Therapeutics Put Options (NKTR)
www.americanbankingnews.com - November 12 at 3:34 AM
Stock Traders Purchase High Volume of Call Options on Nektar Therapeutics (NKTR)Stock Traders Purchase High Volume of Call Options on Nektar Therapeutics (NKTR)
www.americanbankingnews.com - November 12 at 1:56 AM
Jefferies Group Weighs in on Nektar Therapeutics FY2017 Earnings (NKTR)Jefferies Group Weighs in on Nektar Therapeutics' FY2017 Earnings (NKTR)
www.americanbankingnews.com - November 10 at 2:28 PM
Nektar Therapeutics to Post FY2017 Earnings of ($0.76) Per Share, William Blair Forecasts (NKTR)Nektar Therapeutics to Post FY2017 Earnings of ($0.76) Per Share, William Blair Forecasts (NKTR)
www.americanbankingnews.com - November 10 at 2:28 PM
Nektar (NKTR) Q3 Earnings & Sales Surpass, Sales View Up - NasdaqNektar (NKTR) Q3 Earnings & Sales Surpass, Sales View Up - Nasdaq
www.nasdaq.com - November 9 at 8:04 AM
Nektar Therapeutics: Updates To Thesis - Seeking AlphaNektar Therapeutics: Updates To Thesis - Seeking Alpha
seekingalpha.com - November 9 at 8:04 AM
Featured Company News – Nektar Presented Preclinical Data on NKTR-358 at 2017 American College of Rheumatology Annual MeetingFeatured Company News – Nektar Presented Preclinical Data on NKTR-358 at 2017 American College of Rheumatology Annual Meeting
finance.yahoo.com - November 9 at 8:04 AM
Mizuho Reiterates Buy Rating for Nektar Therapeutics (NKTR)Mizuho Reiterates Buy Rating for Nektar Therapeutics (NKTR)
www.americanbankingnews.com - November 8 at 10:26 PM
Insider Selling: Nektar Therapeutics (NKTR) SVP Sells 5,117 Shares of StockInsider Selling: Nektar Therapeutics (NKTR) SVP Sells 5,117 Shares of Stock
www.americanbankingnews.com - November 8 at 7:40 PM
Insider Selling: Nektar Therapeutics (NKTR) SVP Sells 396,323 Shares of StockInsider Selling: Nektar Therapeutics (NKTR) SVP Sells 396,323 Shares of Stock
www.americanbankingnews.com - November 8 at 6:30 PM
Why Nektar Therapeutics Shares Are Soaring 13% HigherWhy Nektar Therapeutics Shares Are Soaring 13% Higher
www.fool.com - November 8 at 3:34 PM
Nektar Therapeutics (NKTR) Releases Quarterly  Earnings Results, Beats Estimates By $0.16 EPSNektar Therapeutics (NKTR) Releases Quarterly Earnings Results, Beats Estimates By $0.16 EPS
www.americanbankingnews.com - November 7 at 6:35 PM
Nektar Therapeutics beats by $0.22, beats on revenueNektar Therapeutics beats by $0.22, beats on revenue
seekingalpha.com - November 7 at 4:44 PM
Nektar Therapeutics (NKTR) Receives New Coverage from Analysts at Cowen and CompanyNektar Therapeutics (NKTR) Receives New Coverage from Analysts at Cowen and Company
www.americanbankingnews.com - November 7 at 11:32 AM
Nektar Therapeutics (NKTR) CEO Sells $1,964,182.38 in StockNektar Therapeutics (NKTR) CEO Sells $1,964,182.38 in Stock
www.americanbankingnews.com - November 3 at 8:36 PM
Nektar Therapeutics (NKTR) to Release Earnings on TuesdayNektar Therapeutics (NKTR) to Release Earnings on Tuesday
www.americanbankingnews.com - November 1 at 11:02 AM
Nektar to Announce Financial Results for the Third Quarter of 2017 on Tuesday ...Nektar to Announce Financial Results for the Third Quarter of 2017 on Tuesday ...
www.prnewswire.com - November 1 at 6:47 AM
Nektar to Announce Financial Results for the Third Quarter of 2017 on Tuesday, November 7, 2017, After Close of U.S.-Based Financial MarketsNektar to Announce Financial Results for the Third Quarter of 2017 on Tuesday, November 7, 2017, After Close of U.S.-Based Financial Markets
finance.yahoo.com - November 1 at 6:47 AM
Zacks: Analysts Expect Nektar Therapeutics (NKTR) Will Post Quarterly Sales of $124.83 MillionZacks: Analysts Expect Nektar Therapeutics (NKTR) Will Post Quarterly Sales of $124.83 Million
www.americanbankingnews.com - October 28 at 12:38 PM
First Week of December 15th Options Trading For Nektar Therapeutics (NKTR)First Week of December 15th Options Trading For Nektar Therapeutics (NKTR)
www.nasdaq.com - October 25 at 8:11 AM
Commit To Buy Nektar Therapeutics At $17, Earn 9.4% Using OptionsCommit To Buy Nektar Therapeutics At $17, Earn 9.4% Using Options
www.nasdaq.com - October 24 at 7:45 AM
Nektar Therapeutics (NKTR) Given Consensus Recommendation of "Buy" by BrokeragesNektar Therapeutics (NKTR) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - October 19 at 6:46 AM
Head to Head Comparison: Senestech (SNES) vs. Nektar Therapeutics (NKTR)Head to Head Comparison: Senestech (SNES) vs. Nektar Therapeutics (NKTR)
www.americanbankingnews.com - October 17 at 8:26 AM
Biotech Stocks on Investors Radar -- Nektar Therapeutics, Ophthotech, PTC Therapeutics, and Spark Therapeutics - PR Newswire (press release)Biotech Stocks on Investors' Radar -- Nektar Therapeutics, Ophthotech, PTC Therapeutics, and Spark Therapeutics - PR Newswire (press release)
www.prnewswire.com - October 17 at 2:35 AM
Financial Review: Nektar Therapeutics (NKTR) & Cleveland BioLabs (CBLI)Financial Review: Nektar Therapeutics (NKTR) & Cleveland BioLabs (CBLI)
www.americanbankingnews.com - October 16 at 10:30 AM
Stephen K. Doberstein Sells 43,677 Shares of Nektar Therapeutics (NKTR) StockStephen K. Doberstein Sells 43,677 Shares of Nektar Therapeutics (NKTR) Stock
www.americanbankingnews.com - October 10 at 7:18 PM
Nektar Therapeutics (NKTR) CEO Howard W. Robin Sells 83,333 SharesNektar Therapeutics (NKTR) CEO Howard W. Robin Sells 83,333 Shares
www.americanbankingnews.com - October 10 at 7:16 PM
$114.14 Million in Sales Expected for Nektar Therapeutics (NKTR) This Quarter$114.14 Million in Sales Expected for Nektar Therapeutics (NKTR) This Quarter
www.americanbankingnews.com - October 9 at 8:44 AM
Notable Friday Option Activity: NKTR, PANW, SKX - NasdaqNotable Friday Option Activity: NKTR, PANW, SKX - Nasdaq
www.nasdaq.com - October 7 at 6:34 AM

Social Media

Financials

Chart

Nektar Therapeutics (NASDAQ NKTR) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.